Reduced exacerbation frequency and prednisone dose in patients with ABPA and asthma treated with dupilumab

Real-world efficacy and safety of dupilumab use in the treatment of asthma

(2021) Somaira Nowsheen et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines—Recommendations on the use of biologicals in severe asthma

(2020) Ioana Agache et al.   ALLERGY

Differential response to biologics in a patient with severe asthma and ABPA: a role for dupilumab?

(2020) Carlo Mümmler et al.   Allergy Asthma and Clinical Immunology

Mechanisms of Dupilumab

(2019) Hani Harb et al.   CLINICAL AND EXPERIMENTAL ALLERGY

D201 DUPILUMAB EFFICACY IN PATIENTS WITH UNCONTROLLED, MODERATE-TO-SEVERE ASTHMA AND SEROLOGIC EVIDENCE OF ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS

(2019) J. Corren et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Dupilumab treatment for allergic bronchopulmonary aspergillosis: A case series

(2019) Richard Paul Ramonell et al.   Journal of Allergy and Clinical Immunology-In Practice

Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria

(2013) R. Agarwal et al.   CLINICAL AND EXPERIMENTAL ALLERGY